RESUMEN
No disponible
Asunto(s)
Masculino , Persona de Mediana Edad , Humanos , Tuberculosis Cutánea/complicaciones , Tuberculosis Cutánea/diagnóstico , Tuberculosis Cutánea/terapia , Tuberculosis Cutánea/epidemiología , Radiografía Torácica/métodos , Rifampin/uso terapéutico , Diagnóstico Diferencial , Mycobacterium tuberculosis , Mycobacterium tuberculosis/aislamiento & purificación , Mycobacterium tuberculosis/patogenicidad , Estudios Retrospectivos , Biopsia/métodosRESUMEN
Lung nocardiosis is a rare disease affecting patients with lymphoreticular neoplasm, immunodeficiency or chronic obstructive pulmonary disease; it can also affect patients who have received transplants. We report a case of lung nocardiosis in which radiographic presentation was acute, with a pattern of multiple bilateral pulmonary nodules ("cannonballs"), requiring us to rule out metastatic disease to arrive at a diagnosis. The patient responded slowly to antibiotic treatment until full resolution.
Asunto(s)
Enfermedades Pulmonares/diagnóstico por imagen , Enfermedades Pulmonares/microbiología , Nocardiosis/diagnóstico por imagen , Nocardia asteroides , Anciano , Femenino , Humanos , RadiografíaRESUMEN
La nocardiosis pulmonar es una enfermedad poco frecuente, que afecta especialmente a individuos con neoplasias linforreticulares, afectados de inmunosupresión, trasplantados o con una enfermedad pulmonar crónica. Presentamos un caso de nocardiosis pulmonar con la característica de que su aparición radiológica fue aguda y con un patrón radiológico en "suelta de globos", lo que obligó a descartar una enfermedad pulmonar metastásica. La paciente presentó una evolución lentamente progresiva con tratamiento antibiótico hasta la total resolución del cuadro (AU)
Asunto(s)
Anciano , Femenino , Humanos , Nocardia asteroides , Nocardiosis , Enfermedades PulmonaresRESUMEN
BACKGROUND: The goal of this study was to determine the prevalence of asbestos-related lung cancer and the importance of the occupational exposure to this inorganic fibre as a risk factor. PATIENTS AND METHODS: We performed a cross-sectional study of 82 patients with lung cancer (mean age 62 SD 9 years) and 53 patients without pleuropulmonary disease (63 SD 13 years). The occupational exposure to asbestos was determined by a questionnaire. We determined the concentration of asbestos bodies (AB) in bronchoalveolar lavage (BAL) (93 patients) or lung tissue (42 patients) after chemical digestion, with the results being expressed as AB/mL BAL or AB/g dry lung, respectively. A concentration higher than 1 AB/mL or 1,000 AB/g was considered as marker of high asbestos burden in lung tissue, which could be potentially responsible for pleuropulmonary disease. The importance of asbestos occupational exposure as a risk factor for lung cancer was determined using logistic regression models. RESULTS: 25 patients with lung cancer reported occupational exposure to asbestos (30%) and in 13 out of them AB were detected in BAL or lung tissue (24%), at high concentrations in 3 cases (4%). Six patients from the group without pleuropulmonary disease reported occupational exposure to asbestos (11%) and in 13 out of them AB were found in some samples (24%), with no case having high concentrations. In the univariate logistic regression analysis, diagnosis of bronchial neoplasia was associated with both smoking (OR 10.10, 95% CI 3.50-29.13) and occupational exposure to asbestos (OR 3.69, 95% CI 1.39-9.77). The association between asbestos exposure and lung cancer persisted statistically significant after adjustment for smoking (OR 2.80, 95% CI 1.00-7.84). CONCLUSION: In Spain, lung cancer was related to occupational exposure to asbestos in 4% of cases, and it appeared to exist a synergistic effect of smoking. Occupational exposure to this inorganic fibre doubles the risk of suffering from lung cancer.
Asunto(s)
Asbestosis/complicaciones , Neoplasias Pulmonares/etiología , Asbestosis/epidemiología , Líquido del Lavado Bronquioalveolar/citología , Estudios de Casos y Controles , Estudios Transversales , Femenino , Humanos , Modelos Logísticos , Neoplasias Pulmonares/epidemiología , Masculino , Persona de Mediana Edad , Oportunidad Relativa , Prevalencia , Fumar/efectos adversos , Fumar/epidemiología , España/epidemiología , Estadística como AsuntoRESUMEN
BACKGROUND: Since coronary artery bypass graft patients remain at risk of coronary artery and bypass graft occlusion after successful surgery, adjunct treatment regimens are under investigation. In a study of the patients of the multicenter Post Coronary Artery Bypass Graft (Post CABG) Trial, 1 mg warfarin was found to have no important effect on coagulation parameters. STUDY DESIGN: The effects of 1, 2 and 3 mg warfarin were evaluated at six-week intervals in 20 Post CABG Trial patients receiving titrated dose increases in comparison to 20 patients of similar age, gender and time from CABG treated with placebo. RESULTS: International normalized ratio (INR) values increased with warfarin dose increments for 1, 2, and 3 mg, respectively (0.95+/-0.16, 1.08+/-0.19, and 1.34+/-0.39) and in comparison to placebo treated patients (dosextreatment p<0.001). Factor VII coagulant activity decreased with warfarin titration (1 mg, 119.0+/-18.3 %; 2 mg, 100.6+/-32.8 %; 3 mg, 95.0+/-27.8 %) and in comparison to placebo (dosextreatment p=0.008). Levels of prothrombin fragment F1.2, tissue plasminogen activator, fibrinogen and von Willebrand factor were unchanged with warfarin dose increments and in comparison to placebo. CONCLUSIONS: At doses up to 3 mg, warfarin acts on the INR through a reduction of factor VII with no effect on the fibrinolytic system, fibrinogen or von Willebrand factor. At these doses F1.2 did not document reduced coagulation activity. The observations of this study were consistent with the decision in the Post CABG Trial to increase the warfarin dose above 1 mg to achieve a distinct effect of warfarin that was less than full anticoagulation.
Asunto(s)
Anticoagulantes/uso terapéutico , Puente de Arteria Coronaria , Enfermedad Coronaria/prevención & control , Oclusión de Injerto Vascular/prevención & control , Complicaciones Posoperatorias/prevención & control , Trombosis/prevención & control , Warfarina/uso terapéutico , Adulto , Anciano , Anticoagulantes/administración & dosificación , Anticoagulantes/efectos adversos , Aspirina/administración & dosificación , Aspirina/uso terapéutico , Enfermedad Coronaria/sangre , Enfermedad Coronaria/cirugía , Relación Dosis-Respuesta a Droga , Quimioterapia Combinada , Factor VII/análisis , Femenino , Fibrinógeno/análisis , Humanos , Relación Normalizada Internacional , Masculino , Persona de Mediana Edad , Fragmentos de Péptidos/análisis , Hemorragia Posoperatoria/inducido químicamente , Protrombina/análisis , Recurrencia , Vena Safena/patología , Vena Safena/trasplante , Activador de Tejido Plasminógeno/análisis , Resultado del Tratamiento , Warfarina/administración & dosificación , Warfarina/efectos adversos , Factor de von Willebrand/análisisRESUMEN
PURPOSE: The complications of heparin-induced thrombocytopenia include thrombosis and death. The purpose of the study was to determine whether early heparin cessation can prevent these outcomes. SUBJECTS AND METHODS: We performed a retrospective analysis of consecutive patients with heparin-induced thrombocytopenia diagnosed by platelet aggregometry. Demographic, clinical, and laboratory findings were compared in patients by whether heparin treatment was stopped early (< or = 48 hours) or late (>48 hours) after the onset of thrombocytopenia, as well as between patients with and without thrombosis. Thrombocytopenia was defined as a 50% decline in baseline platelet counts or an absolute platelet count < 100,000/mm3. RESULTS: Of the 113 patients, 38% developed thrombosis and 27% died. One-half of patients had thrombosis diagnosed >24 hours after heparin cessation. No difference in thrombosis or mortality was found in the 40 patients with early heparin cessation [mean (+/-SD) time of cessation 0.7 +/- 0.6 days] compared with the 73 patients with late heparin cessation (5 +/- 3 days). Thrombosis >24 hours after heparin cessation occurred in 61% of the patients in the early group and in 40% of the late group (P = 0.17). In a multivariate analysis, only a lower nadir of the platelet count (percent of baseline) was associated with thrombosis. Neither thrombosis nor the time to heparin cessation were associated with mortality. CONCLUSIONS: Early heparin cessation was not effective in reducing morbid events in patients with heparin-induced thrombocytopenia. Treatment strategies other than heparin cessation alone should be considered in patients with this condition.
Asunto(s)
Anticoagulantes/administración & dosificación , Anticoagulantes/efectos adversos , Heparina/administración & dosificación , Heparina/efectos adversos , Trombocitopenia/inducido químicamente , Trombocitopenia/prevención & control , Adulto , Anciano , Anciano de 80 o más Años , Esquema de Medicación , Femenino , Humanos , Masculino , Registros Médicos , Persona de Mediana Edad , Análisis Multivariante , Oportunidad Relativa , Agregación Plaquetaria , Estudios Retrospectivos , Trombocitopenia/diagnóstico , Trombosis/mortalidad , Trombosis/prevención & control , Factores de Tiempo , Resultado del TratamientoRESUMEN
Although coronary bypass graft surgery has increased the survival and quality of life of many individuals, patients remain at risk of restenosis and thrombotic occlusion of the coronary arteries and bypass grafts. In the screening period for participation in the multicenter Post Coronary Artery Bypass Graft (Post CABG) trial, the effects of 1 mg daily warfarin were evaluated using paired patient samples collected prior to and after at least 21 days of treatment. In stable patients (n = 40; 39 males 1 female; 51-74 years old) who previously had undergone coronary artery revascularization (1-10 years), no alterations in prothrombin time, international normalized ratio (INR), prothrombin fragment 1.2, or the hemostatic risk factors factor VII antigen and coagulant activity, von Willebrand's factor, fibrinogen, tPA, or PAI-1 were associated with the 1 mg daily warfarin treatment. The observations reported here supported the Post CABG Studies Steering Committee decision to treat patients with 1-4 mg warfarin daily adjusted to achieve INRs not to exceed 2. 0 consistent with low-intensity therapy.
Asunto(s)
Anticoagulantes/administración & dosificación , Puente de Arteria Coronaria , Warfarina/administración & dosificación , Anciano , Anticoagulantes/uso terapéutico , Antígenos/análisis , Factor VII/análisis , Femenino , Fibrinógeno/análisis , Humanos , Masculino , Persona de Mediana Edad , Fragmentos de Péptidos/análisis , Inhibidor 1 de Activador Plasminogénico/sangre , Cuidados Posoperatorios , Protrombina/análisis , Tiempo de Protrombina , Fumar/sangre , Activador de Tejido Plasminógeno/análisis , Warfarina/uso terapéutico , Factor de von Willebrand/análisisRESUMEN
UNLABELLED: Asbestos bodies (AB) in respiratory secretions in bronchoalveolar lavage (BAL) identify subjects with lower airway AB content is a potential cause of pleural or pulmonary disease. The precision of this qualitative measure, however, has not been adequately analyzed. OBJECTIVE: To determine the sensitivity and specificity of finding AB in BAL fluid by conventional qualitative cytology in comparison with the quantification of AB in BAL fluid. METHOD: BAL samples from 40 subjects exposed to asbestos (mean age 59.2 years; men/women 36/4) were processed in the following ways: 1) qualitative cytology and 2) quantification of AB in BAL fluid expressed as AB/ml. The concentration of AB in BAL fluid was considered the gold standard (upper limit of normal 1 AB/ml) for determining the precision of qualitative cytology. RESULTS: In 9 of the 40 cases (22.5%) AB was found in BAL liquid cytology, but in only five of them were AB counts greater than 1 AB/ml. AB counts also showed concentrations greater than 1 AB/ml for four patients whose qualitative results were negative. The sensitivity of a qualitative AB-positive finding for identifying subjects with potentially disease-causing AB concentrations was 0.55, while specificity was 0.87. We conclude that a qualitative finding of AB in BAL fluid is adequately specific, but that sensitivity is very low, an indication that AB concentration in BAL should be determined to adequately screen for patients at high risk of developing disease.
Asunto(s)
Amianto/análisis , Líquido del Lavado Bronquioalveolar/química , Carcinógenos/análisis , Femenino , Humanos , Masculino , Persona de Mediana Edad , Sensibilidad y EspecificidadRESUMEN
The benign metastasizing leiomyoma is an uncommon variety of leiomyoma, tumor derived from smooth muscular tissue. The benign metastasizing leiomyoma affects a middle age women, with antecedents of uterine leiomyoma, the pulmonary lesions appeared as a multiple nodules, without systemic affectation. We present three cases of benign metastasizing leiomyoma that de diagnosis was made for biopsy by thoracotomy; and in one case the markers from estrogens' receivers were positive.
Asunto(s)
Leiomioma/patología , Neoplasias Pulmonares/secundario , Biopsia , Femenino , Humanos , Leiomioma/diagnóstico , Pulmón/patología , Neoplasias Pulmonares/diagnóstico , Neoplasias Pulmonares/patología , Persona de Mediana Edad , Radiografía Torácica , Tomografía Computarizada por Rayos X , Neoplasias Uterinas/patología , Útero/patologíaRESUMEN
Heparin-induced thrombocytopenia is one of the most difficult problems facing clinicians today. Despite recent understanding of the pathophysiology of this disorder, there are many unresolved issues about diagnosis, prevention, and treatment. In this article, difficulties physicians encounter when faced with a suspected heparin-induced thrombocytopenia patient will be reviewed as well as our experience in 113 patients with heparin-induced thrombocytopenia which highlights the failure of current preventive strategies for heparin-induced thrombocytopenia. The experience of using warfarin in 51 patients with heparin-induced thrombocytopenia will also be reviewed.
Asunto(s)
Fibrinolíticos/efectos adversos , Heparina/efectos adversos , Trombocitopenia/inducido químicamente , Trombocitopenia/prevención & control , Fibrinolíticos/uso terapéutico , Heparina/uso terapéutico , Humanos , Trombina/antagonistas & inhibidores , Warfarina/uso terapéuticoRESUMEN
Choreoathetosis, seizures, and impaired mental development continue to occur in children undergoing cardiopulmonary bypass (CPB) and profound hypothermia with or without circulatory arrest. Although there is some evidence that the hypothermia itself may be causing these neurologic problems, skepticism remains because of lack of evidence from experimental studies simulating the clinical setting. In this experimental study, we examined the effect of profound and moderate hypothermia on the brain while maintaining normal flow rates during CPB. Ten adult mongrel dogs equally divided into two groups were anesthetized and subjected to CPB and varying levels of hypothermia (group 1, < or = 15 degreesC; group 2, < or = 2 degreesC). Both groups were kept at the desired temperature for 1 hour prior to rewarming and discontinuation of CPB. The dogs were euthanized 4-6 weeks later and neuropathologic studies were performed. The mean CPB flow rates during cooling and at the desired rectal temperature were comparable in both groups: group 1, 108 +/- 10 ml/kg/min versus 106 +/- 7 ml/kg/min in group 2 (p = NS) and 95 +/- 12 ml/kg/min in group 1 versus 101 +/- 5 ml/kg/min in group 2 (p = NS). Because of the difference in temperature between the two groups, the mean cooling time (onset of CPB to desired rectal temperature) was longer in group 1 (70 +/- 14 minutes) than in group 2 (28 +/- 11 minutes, p = 0.007). Hence, the total mean CPB time was also longer in group 1 (198 +/- 25 minutes) than in group 2 (143 +/- 13 minutes, p = 0.002). The lowest mean blood and rectal temperature achieved in group 1 were 11 +/- .9 degreesC and 12 +/- 1 degreesC versus 29 +/- .4 degreesC (p < 0.001) and 30 +/- .6 degreesC (p = 0.001), respectively, in group 2 (p = 0.001). Neuronal loss and degeneration was noted in all dogs in group 1 ranging from 2 to 8 cells per 1000 cells counted compared to none in group 2 (p = 0.05). These lesions occurred in both the basal ganglia and the cortex, although they were more marked in the caudate when compared to the cortex and cerebellum. Both in the cortex and in the caudate, neuronal loss was more marked around the capillaries. We conclude that the use of profound hypothermia of < or =15 degreesC and maintenance of normal flow rates during cooling at this temperature for 1 hour produces neuronal loss and degeneration in the brain. These lesions being more marked around capillaries points to the vulnerability of the neurons, probably because of their high lipid content to injury from the cold perfusate.
Asunto(s)
Encéfalo/patología , Hipotermia Inducida/efectos adversos , Animales , Ganglios Basales/patología , Puente Cardiopulmonar , Corteza Cerebral/patología , Perros , Estudios de Evaluación como AsuntoAsunto(s)
Alveolitis Alérgica Extrínseca , Industria para Empaquetado de Carne , Enfermedades Profesionales , Alveolitis Alérgica Extrínseca/diagnóstico , Alveolitis Alérgica Extrínseca/etiología , Femenino , Humanos , Persona de Mediana Edad , Enfermedades Profesionales/diagnóstico , Enfermedades Profesionales/etiologíaAsunto(s)
Bronquios , Cuerpos Extraños/etiología , Adulto , Femenino , Humanos , Inhalación , MasculinoRESUMEN
The early stages of venous thrombosis originate at selective sites of reduced blood flow in the apices of venous valves. Stagnation of venous flow results in the formation of a platelet-fibrin thrombus, which serves as the nidus for thrombus propagation. Stasis alone, however, does not result in thrombosis necessarily. The presence of activated coagulation factors is essential. The major predisposing factors to venous thrombus are activation of blood coagulation and venous stasis. In contrast to venous thrombus formation, vascular abnormalities are the most important causative factor in arterial thrombosis.
Asunto(s)
Enfermedades Cardiovasculares/etiología , Trombosis/etiología , Enfermedad Aguda , Enfermedades Cardiovasculares/cirugía , Embolectomía , Urgencias Médicas , Humanos , Trombectomía , Trombosis/cirugíaRESUMEN
Shock is a rare complication of massive pleural effusion and few cases have been described in the literature. Massive pleural effusion can cause right ventricular collapse due to transfer of pressure from the pleura to the pericardial space, creating a medical emergency requiring thoracocentesis for evacuation. We describe the case of a man with submassive right pleural effusion seen in the pneumology unit of our hospital. During the admission process, he suffered arterial hypotension and cardiorespiratory arrest requiring orotracheal intubation and mechanical ventilation. Massive pleural effusion with mediastinal displacement could be seen on a chest film. Symptoms resolved after thoracocentesis to evacuate the space and tubes were removed 24 hours after the event.
Asunto(s)
Paro Cardíaco/etiología , Derrame Pleural/complicaciones , Choque/etiología , Carcinoma de Pulmón de Células no Pequeñas/complicaciones , Paro Cardíaco/terapia , Humanos , Intubación Intratraqueal , Neoplasias Pulmonares/complicaciones , Masculino , Persona de Mediana Edad , Derrame Pleural/diagnóstico por imagen , Derrame Pleural/terapia , Punciones , Respiración Artificial , Tomografía Computarizada por Rayos XRESUMEN
BACKGROUND: Aprotinin has recently been approved for clinical use in cardiopulmonary bypass. Although unfractionated heparin has been the only anticoagulant widely used for cardiopulmonary bypass, disadvantages involving heparin have led to ongoing investigations of alternative anticoagulant agents. METHODS: The objective of this study was to evaluate the efficacy of aprotinin in combination with other anticoagulant agents, specifically low molecular weight heparin and recombinant hirudin, using a dog model of cardiopulmonary bypass. RESULTS: The blood conservation resulting from the use of aprotinin was observed only with unfractionated heparin. Efficacy of anticoagulation as measured by protein deposits in the bypass circuit filter revealed an unexpected reduction in the quantity of deposits when aprotinin was used in combination with low molecular weight heparin. CONCLUSIONS: As alternative anticoagulant agents are sought, the potential benefits of aprotinin in the reduction of operative blood loss must be evaluated independently for each anticoagulant agent.
Asunto(s)
Anticoagulantes/uso terapéutico , Aprotinina/uso terapéutico , Puente Cardiopulmonar , Hemostáticos/uso terapéutico , Animales , Anticoagulantes/administración & dosificación , Antitrombinas/administración & dosificación , Antitrombinas/uso terapéutico , Aprotinina/administración & dosificación , Coagulación Sanguínea/efectos de los fármacos , Pérdida de Sangre Quirúrgica/prevención & control , Puente Cardiopulmonar/instrumentación , Modelos Animales de Enfermedad , Perros , Combinación de Medicamentos , Filtración/instrumentación , Hemostáticos/administración & dosificación , Heparina/administración & dosificación , Heparina/uso terapéutico , Heparina de Bajo-Peso-Molecular/administración & dosificación , Heparina de Bajo-Peso-Molecular/uso terapéutico , Terapia con Hirudina , Hirudinas/administración & dosificación , Masculino , Tiempo de Tromboplastina Parcial , Proteínas RecombinantesRESUMEN
BACKGROUND: Symptomatic improvement of a patient's hemodynamic condition during intraaortic balloon counterpulsation (IABC) is considered to result largely from a reduction in afterload. Afterload can be accurately quantified by arterial input impedance measurements. Here we report the effect of IABC on arterial impedance in humans. METHODS: To characterize the effects of IABC on arterial input impedance, impedance measurements were obtained using aortic annulus Doppler flow and pressure from the aortic balloon catheter. Impedance spectra were compared between the cardiac cycles preceding and following the cycle with IABC in 25 patients. RESULTS: Intraaortic balloon counterpulsation increased stroke volume (23%; p = 0.001), reduced myocardial oxygen demand (11%; p = 0.02), and decreased the aortic pressure at the onset of systole (16%; p = 0.001). There was also a decrease in systemic vascular resistance (24%; p = 0.001), characteristic arterial impedance (21%; p = 0.002), and pulse wave reflection (20%; p = 0.006). Linear regression analysis showed that an increase in stroke volume was predicted only by the decrease in systemic vascular resistance (r = -0.81; p = 0.001). CONCLUSIONS: The reduction in systemic vascular resistance appeared to be the major mechanism by which IABC improved cardiac pumping efficiency. This effect may result from the passive distention of the peripheral vascular bed due to the propagation of the balloon-augmented diastolic pressure through the arterial system.
Asunto(s)
Contrapulsador Intraaórtico , Resistencia Vascular , Anciano , Anciano de 80 o más Años , Puente Cardiopulmonar , Puente de Arteria Coronaria , Femenino , Cardiopatías/fisiopatología , Cardiopatías/cirugía , Hemodinámica , Humanos , Masculino , Persona de Mediana Edad , Volumen SistólicoRESUMEN
A total of 288 patients underwent heart transplantation at Loyola University Medical Center over a 8 1/2-year period starting in March, 1984. Of these patients, 54 were identified as having allograft coronary arteriopathy. Diagnosis was made on the basis of abnormal findings on coronary angiography in 44 patients; either an autopsy or explanted heart revealed the diagnosis in the remainder. A total of 279 abnormal lesions were identified by coronary angiography, and over 70% of these stenoses were discrete and located in large epicardial vessels. The left ventricular ed-diastolic pressure demonstrated a steady rise over time (2.5 mmHg/year), and also correlated with the degree of allograft coronary arteriopathy stenosis. The rate of stenosis progression was 33% per year from the time of initial allograft coronary arteriopathy development. Actuarial survival rate was lower than that of patients with arteriopathy. In conclusion, first, the majority of allograft coronary arteriopathy stenoses detected on coronary angiography are discrete, involve large epicardial vessels, and progress rapidly over time. Second, left ventricular end-diastolic pressure seems to reflect the degree of allograft coronary arteriopathy stenosis, and may prove to be a useful indicator of left ventricular dysfunction related to allograft coronary arteriopathy. Third, patients with allograft coronary arteriopathy show a decreased actuarial survival rate.
Asunto(s)
Enfermedad Coronaria/fisiopatología , Trasplante de Corazón/fisiología , Análisis Actuarial , Gasto Cardíaco , Presión Venosa Central , Angiografía Coronaria , Enfermedad Coronaria/complicaciones , Enfermedad Coronaria/diagnóstico por imagen , Enfermedad Coronaria/patología , Vasos Coronarios/patología , Progresión de la Enfermedad , Estudios de Seguimiento , Trasplante de Corazón/diagnóstico por imagen , Trasplante de Corazón/patología , Humanos , Illinois , Presión Esfenoidal Pulmonar , Estudios Retrospectivos , Tasa de Supervivencia , Trasplante Homólogo , Disfunción Ventricular Izquierda/etiología , Presión VentricularRESUMEN
BACKGROUND: Clinical performance of a left ventricular assist device is assessed via hemodynamic parameters and end-organ function. This study examined effect of a left ventricular assist device on human neurophysiology. METHODS: This study evaluated the time course change of cardiac autonomic activity of 3 patients during support with a left ventricular assist device before cardiac transplantation. Cardiac autonomic activity was determined by power spectral analysis of short-term heart rate variability. The heart rate variability before cardiac transplantation was compared with that on the day before left ventricular assist device implantation. RESULTS: The standard deviation of the mean of the R-R intervals of the electrocardiogram, an index of vagal activity, increased to 27 +/- 7 ms from 8 +/- 0.6 ms. The modulus of power spectral components increased. Low frequency (sympathetic activity) and high frequency power (vagal activity) increased by a mean of 9 and 22 times of each baseline value (low frequency power, 5.2 +/- 3.0 ms2; high frequency power, 2.1 +/- 0.7 ms2). The low over high frequency power ratio decreased substantially, indicating an improvement of cardiac sympatho-vagal balance. CONCLUSIONS: The study results suggest that left ventricular assist device support before cardiac transplantation may exert a favorable effect on cardiac autonomic control in patients with severe heart failure.